Govt's scientific groups deliberating on need for booster dose of Covid-19

ICMR Director General Balram Bhargava said discussions are going on to look at different aspects of booster dose

Covid-19 vaccines, Coronavirus vaccines, Vaccination
Press Trust of India New Delhi
3 min read Last Updated : Dec 24 2021 | 7:44 PM IST

The government's scientific groups are deliberating on the need for booster dose of COVID-19 and they are reviewing all data from across the world as well as from India, officials said on Friday.

Addressing a press conference, ICMR Director General Balram Bhargava said discussions are going on to look at different aspects of booster dose.

"There is a COVID working group, which has debated on it several times that those recommendations to the subcommittee of the National Technical Advisory Group of immunisation following which it goes to the main technical advisory group of immunisation and then to NEGVAC which will then be accepted by the Ministry of Health," he said.

"So, deliberations are going on and we are reviewing all the scientific data from across the world as well as from India. We are deliberating and we are formulating our policy," he said.

Union Health Secretary Rajesh Bhushan said the government has very clearly articulated the position that it would be governed by science and scientific evidence on deciding on the need and timing for additional doses and for lowering the age of vaccination.

"So our stand remains the same. And when we say science and scientific evidence, I did refer to certain aspects of science and scientific evidence. One aspect relates to antibody titers and their behaviour over a period of time. The other aspect relates to T cells and their behaviour over a period of time," Bhushan said.

"The third aspect relates to hybrid immunity, where you take one dose of vaccination and then get afflicted by the disease, then recover then take the second dose. So these are issues that men of science are deliberating," he said.

Quoting WHO Director-General Tedros Adhanom Ghebreyesus, Bhushan said, "No country can boost its way out of the pandemic and boosters cannot be seen as a ticket to go ahead with planned celebrations without the need for other precautions".

According to WHO expert Abdi Mahamud, Bhushan said, "Although we are seeing a reduction in the neutralization antibodies, almost all data shows T-cells remain intact, that is what we really require."

"While the antibody defences from some courses have been undermined, there has been hope that T-cells, the second pillar of an immune response, can prevent severe disease by attacking infected human cells," Mahamud was quoted as saying by Bhushan.

National Expert Group on vaccine administration for Covid (NEGVAC) and National Technical Advisory Group on Immunization (NTAGI) are deliberating and considering scientific evidence related to justification for booster dose against Covid, the Centre informed Parliament recently.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Dec 24 2021 | 7:44 PM IST

Next Story